Concerns about NICE-approved medicines for rare and less common cancers

Two days ago the Health and Social Care Information Centre published its statistics on the use of NICE-approved medicines yesterday.

The Telegraph also carried a comment article from the Rarer Cancer Foundation:

Andrew Wilson, Chief Executive Officer of the Rarer Cancers Foundation argues:

– The bar for NICE recommendation is very high – it is imperative that when NICE approves a medicine that it gets used appropriately

– The variation between actual and expected levels of usage and between usage in different providers is worrying and needs explaining

– The NHS needs to stop dismissing the factors underpinning variation as ‘complex’ and start explaining to patients and the public why variation happens

– Implementation of guidance should be made a key part of the hospital inspection process

The Rarer Cancers Foundation | Telephone: 0208 692 2910 | Mobile: 07973118290 | (includes less common cancers)


About bmitzi

Medical writer, author, artist. Cancer campaigner. Aiming always to improve health services and bring compassion into health care.
This entry was posted in Campaigns, Compassion in healthcare, patient safety, rarer and uncommon cancers and tagged , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s